About 95% of rare disorders don’t have a treatment for it, and even in cases where treatment is available or a clinical trial is being conducted, not everyone across the world has equal access to it. That’s what’s happening now in the context of Duchenne Muscular Dystrophy. Here to help us dive into this and why equitable access to treatments matter, we speak to Catherine Jayasuriya, Founder & Executive Director, Coalition Duchenne, and Nadiah Hanim Abdul Latif, President, Malaysia Rare Disorders Society.



Image Credit: Catherine Jayasuriya

About 95% of rare disorders don’t have a treatment for it, and even in cases where treatment is available or a clinical trial is being conducted, not everyone across the world has equal access to it. That’s what’s happening now in the context of Duchenne Muscular Dystrophy. Here to help us dive into this and why equitable access to treatments matter, we speak to Catherine Jayasuriya, Founder &amp; Executive Director, Coalition Duchenne, and Nadiah Hanim Abdul Latif, President, Malaysia Rare Disorders Society.Image Credit: Catherine Jayasuriya

Wander and be enlightened by the endlessly fascinating inner universe that is the human body. We speak with experts, Nobel laureates, cancer survivors and healthcare workers who share their unique perspectives on wellness and living and the latest medical research.

Advertisement